Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : F. Hoffmann-La Roche Ltd
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study to investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients
Part 1: •To evaluate the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7034067 in patients with Type 2 and Type 3 (ambulant or non-ambulant) SMA, and to select the dose f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249
- To evaluate the long-term safety and tolerability profile of RO4389620 at a dose, ranging from 25 mg BID to 100 mg BID, administered alone or in combination with metformin during 52-week treatment i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/ tolerability and pharmacokinetics of five dose levels of RO4998452 in patients with type 2 diabetes mellitus
• To determine the absolute change in HbA1c concentration from baseline to the end of the treatment period compared to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors
The main objective is to evaluate the percentage of patients that do not experience progression during the first 18 weeks of treatment with Atezolizumab in patients affected by advanced solid tumors.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients with Spinal Muscular Atrophy
• To evaluate the safety of olesoxime in patients with Spinal Muscular Atrophy (SMA)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma
1. To demonstrate that the combination of bevacizumab and FOLFOX-4 is superior to FOLFOX-4 alone in terms of disease-free survival in chemotherapy-naïve patients who underwent surgery with curative in...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
To provide Tarceva to patients with advanced stage IIIB /IV Non Small Cell Lung Cancer who have received at least one course of standard systemic chemotherapy or radiation therapy or who are in the i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A Study of Lebrikizumab in Patients with Chronic Obstructive Pulmonary Disease
• To evaluate the efficacy of lebrikizumab compared with placebo in improving lung function, as measured by the absolute change in pre-bronchodilator forced expiratory volume in one second (FEV1) in p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
A blinded phase II study to evaluate the efficacy and safety of 2 different treatments arms (RO5520985 plus standard chemotherapy FOLFOX versus bevacizumab plus standard chemotherapy FOLFOX) in patients who have not been treated before for their metastatic disease of colorectal cancer. Estudio ciego de fase II para evaluar la eficacia y seguridad en 2 grupos de tratamiento diferentes (RO5520985 más quimioterapia estándar FOLFOX en comparación con bevacizumab más quimioterapia estándar FOLFOX) en pacientes con cáncer colorrectal metastásico sin tratamiento previo
The primary objective of Study BP29262 is to estimate the efficacy of RO5520985 in combination with oxaliplatin, folinic acid, and 5 fluorouracil (mFOLFOX-6) vs. bevacizumab in combination with mFOLFO...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
F. Hoffmann-La Roche Ltd
MAJ Il y a 5 ans
Evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastro-esophageal junction and gastric cancer
To compare overall survival (OS) in patients treated with pertuzumab in addition to Herceptin® (trastuzumab) plus fluoropyrimidine plus cisplatin (TFP) versus patients treated with placebo in addition...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant